Pelage Pharmaceuticals is a regenerative-medicine biotechnology company focused on first-in-class treatments for hair loss in both men and women. Its science centers on stem cell biology and metabolism, aiming to restore the body’s natural ability to grow hair by reactivating dormant hair-follicle stem cells. The company’s lead asset, PP405, is a non-invasive topical small molecule currently being evaluated in Phase 2a clinical trials. Proceeds from the most recent financing will be directed toward advancing PP405 through mid-stage development and expanding Pelage’s broader pipeline of hair-regeneration therapies. Led by CEO Daniel Gil, Ph.D., Pelage’s leadership team includes co-founder and President William Lowry, Ph.D. The firm has also strengthened its governance, appointing Cathy Friedman (GV) as Board Chair and adding Richard Heyman, Ph.D. (ARCH) to its board. The fresh capital positions Pelage to accelerate clinical progress and prepare for later-stage studies.

Total raised

$151M

Funding rounds

3

Latest round

Series B

Latest activity

Oct 2025